- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05742568
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
November 13, 2023 updated by: Yongquan Shi, Xijing Hospital of Digestive Diseases
This study was conducted to investigate the effects of high-dose diphtherapy and bismuth quadruple therapy on H. pylori eradication on intestinal microecology, to clarify the changes in intestinal microbiota diversity and structure before and after the two treatment regimens, and to explore the relationship between different treatment regimens and intestinal microbiota dysbiosis; to further guide the safety and drug resistance of H. pylori eradication by the two treatment regimens.
The expected results are to observe the changes of intestinal microbiota diversity and structure before and after treatment with the two treatment regimens.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
The trial can be divided into three phases.
- Enrollment screening phase: patients who had been clearly diagnosed with Hp infection and had not received antibiotic therapy and met the inclusion and exclusion criteria were informed and signed informed consent forms, their basic data information was collected, medical history and laboratory tests before enrollment were taken; if they met the requirements of the trial protocol they were included in the study, and patients' stools were collected for 16S rRNA gene sequencing.
- Treatment period: Patients were enrolled according to a randomized number table provided in advance by a third party, and patients were randomized in a 1:1 ratio to high-dose diphtherapy and bismuth quadruple therapy to receive 2 weeks of Hp eradication treatment. During the treatment period, patients were provided with written instructions on how to take the medication, instructed on the correct way to take the medication, and improved their compliance; patients were asked to record their symptoms and adverse reactions during the medication period, and were informed of the visiting telephone number and visiting WeChat, so that they could keep in touch with the investigator at any time.
- Follow-up period: At the end of treatment (i.e., day 14 from the start of treatment), patients were asked to return at that time to have their stools sequenced for 16S rRNA gene, and 6 weeks after the end of treatment (i.e., day 56 from the start of treatment), patients were asked to return at that time to undergo rapid urease test (RUT), 13C/14C-urea breath test (13C/14C-UBT), or fecal Hp antigen test. ) or fecal Hp antigen assay (HpSA), with the results recorded on a CRF form, and the patient's stool collected for 16S rRNA gene sequencing.
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yongquan Shi, Ph. D
- Phone Number: 86-29-84771515
- Email: shiyquan@fmmu.edu.cn
Study Contact Backup
- Name: Tengteng Wang
- Phone Number: 86-18891515679
- Email: 18891515679@163.com
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Recruiting
- Xijing Hosipital of Digestive Disease
-
Contact:
- Yongquan Shi, Ph. D
- Phone Number: 86-29-84771515
- Email: shiyquan@fmmu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 to 70 years, regardless of gender.
- Patients with definite Hp infection (positive for either 13C/14C urea breath test, rapid urease test, and fecal Hp antigen test) and who have not received H. pylori eradication therapy.
- Voluntary Hp eradication therapy.
- Women of childbearing potential are required to use a medically advisable form of contraception during the trial and for 30 days after the trial ends.
Exclusion Criteria:
- Patients who have had a definite diagnosis of Hp infection and have been treated with antibiotic eradication therapy.
- Patients with contraindications to or allergies to the study drug.
- Patients with severe organ damage and complications (e.g., cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine disease
- Continuous use of anti-ulcer drugs, antibiotics or bismuth complexes (taken at least 2 weeks prior to the screening for Hp infection)
- Pregnant and lactating women.
- Having undergone upper gastrointestinal surgery.
- Have symptoms of dysphagia.
- Evidence of bleeding or iron deficiency anemia.
- History of malignancy.
- History of drug or alcohol abuse within the last 1 year.
- Systemic application of glucocorticoids, non-steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except for the use of aspirin ≤100 mg/d)
- Those with psychiatric disorders.
- Received other clinical trials within the past 3 months
- Refusal to sign the informed consent form.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High-dose dual therapy
Esomeprazole Enteric Tablets 40mg, 3 times/day; Amoxicillin Capsules 1000mg, 3 times/day.The course of all drugs is two weeks.
|
High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID
Other Names:
High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID
Other Names:
BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
Other Names:
Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
|
Active Comparator: Bismuth Quadruple Therapy
Esomeprazole Enteric Tablets 40mg, 2 times/day; Amoxicillin Capsules 1000mg, 2 times/day; Clarithromycin Tablets 500mg, 2 times/day; Colloidal Bismuth Tartrate Capsules 220mg, 2 times/day.The course of all drugs is two weeks.
|
High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID
Other Names:
High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID
Other Names:
BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
Other Names:
Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the diversity and structure of fecal microbiota
Time Frame: before treatment,1day after treatment,6 weeks after treatment
|
Feces from subjects before treatment , after eradication treatment , and at week 6 after eradication treatment were analyzed for gut microbiota diversity by 16S rRNA gene sequencing, including alpha diversity (representing the abundance of species in the microbial ecosystem, i.e., the number of different species, and evenness, i.e., similar abundance or dominance of some species over others) and beta diversity (representing the difference in microbial composition in one environment compared to another).We will explore the changes in intestinal microbiota diversity and structure before and after treatment with both treatment regimens.
|
before treatment,1day after treatment,6 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eradication rate of Helicobacter pylori
Time Frame: 28 days after treatment
|
The end point of this study is H.pylori eradication,established by negative [13C] urea breath test (DOB value below 3.9)28 days after the end of eradication.
|
28 days after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Yongquan Shi, Ph. D, Xijing Hosipital of Digestive Disease
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2022
Primary Completion (Estimated)
December 2, 2023
Study Completion (Estimated)
March 10, 2024
Study Registration Dates
First Submitted
February 3, 2023
First Submitted That Met QC Criteria
February 14, 2023
First Posted (Actual)
February 24, 2023
Study Record Updates
Last Update Posted (Estimated)
November 14, 2023
Last Update Submitted That Met QC Criteria
November 13, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Signs and Symptoms, Digestive
- Gastrointestinal Diseases
- Stomach Diseases
- Gastroenteritis
- Intestinal Diseases
- Duodenal Diseases
- Gastritis
- Dyspepsia
- Peptic Ulcer
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Protein Synthesis Inhibitors
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Antacids
- Amoxicillin
- Clarithromycin
- Esomeprazole
- Bismuth
Other Study ID Numbers
- KY20222310-C-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastritis
-
Daewoong Pharmaceutical Co. LTD.CompletedAcute Gastritis | Chronic GastritisKorea, Republic of
-
Addpharma Inc.CompletedAcute Gastritis | Chronic GastritisKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedAcute Gastritis | Chronic GastritisKorea, Republic of
-
Dong-A ST Co., Ltd.UnknownAcute Gastritis | Chronic GastritisKorea, Republic of
-
Instituto Ecuatoriano de Enfermedades DigestivasCompletedGastritis | Atrophic Gastritis | Helicobacter Pylori Associated GastritisEcuador
-
Dong-A ST Co., Ltd.RecruitingGastritis Acute | Gastritis ChronicKorea, Republic of
-
Korea Otsuka Pharmaceutical Co., Ltd.RecruitingAcute Gastritis | Chronic GastritisKorea, Republic of
-
Dong-A ST Co., Ltd.CompletedAcute Gastritis | Chronic GastritisKorea, Republic of
-
Dong-A Pharmaceutical Co., Ltd.UnknownAcute Gastritis | Chronic GastritisKorea, Republic of
-
Peking University First HospitalRecruitingChronic Atrophic GastritisChina
Clinical Trials on Esomeprazole
-
TakedaCompletedHealthy ParticipantsUnited States
-
National Taiwan University HospitalMinistry of Science and Technology, Taipei, TaiwanCompleted
-
AstraZenecaCompletedRefractory Reflux EsophagitisJapan
-
Chinese University of Hong KongCompletedBleeding | Peptic UlcerChina
-
Bio-innova Co., LtdNot yet recruiting
-
Onconic Therapeutics Inc.Completed
-
Bio-innova Co., LtdNot yet recruiting
-
Chong Kun Dang PharmaceuticalCompleted
-
AstraZenecaCompletedGastroesophageal Reflux Disease (GERD)United States, France, Poland, Germany
-
Chinese University of Hong KongTerminatedGastrointestinal HemorrhageChina